Mayne Pharma Group Ltd. · ASX:MYX
Mayne Pharma — FY2025 Earnings Presentation
24 slides from Mayne Pharma's earnings presentation, Aug 29, 2025
Slide 1: FY25 Results Presentation
Mayne Pharma Group Limited FY25 Results Presentation Shawn Patrick O’Brien (CEO) Aaron Gray (CFO) 29 August 2025
Slide 2: Disclaimer
Disclaimer The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited Financial Statements and market disclosures. This material is not intended to be relied upon as advice to investors or potential inves
Slide 3: FY25 Financial Highlights
FY25 Financial Highlights1 Revenue growth and targeted operating expenditure delivered 105% increase in underlying EBITDA versus the pcp $408.1m 60.6% $47m Revenue Gross margin Underlying EBITDA2 up 5% FY24 up from 56.3% FY24 up 105% from $22.9m FY24 $109.7m $45.4m $100.4m Total direct segment Opera
Slide 4: FY25 Operating Highlights
FY25 Operating Highlights Women’s Health Dermatology International • 30% growth in demand cycles1 for • Revenues impacted by competitor • Modernisation upgrade complete, driving NEXTSTELLIS®, compared to pcp, driven by launches (AG ORACEA®), portfolio gross end to end manufacturing capability and ne
Slide 5: FY25 Group Financial Performance
FY25 Group Financial Performance
Slide 6: Group Continuing Operations Overview: Strong Underlying EBITDA Result
Group Continuing Operations Overview: Strong Underlying EBITDA Result Change vs Change vs A$ million1 FY25 FY24 FY24 ($) FY24 (%) Reported Revenue 408.1 388.4 19.7 5% Reported Gross Profit 247.3 218.8 28.5 13% Reported Direct Contribution 109.7 88.5 21.2 24% Reported EBITDA 18.4 (92.5) 110.9 120% 2
Slide 7: Direct Opex Growth and Contribution
Direct opex growth in line with revenue, solid growth in contribution (A$m) 1 Segment Performance FY24 FY25 Change (A$ million) FY25 Commentary2 Revenue 388.4 408.1 5% Gross Profit 218.8 247.3 13% • Improvement in gross margins to 60.6% from 56.3% in Direct Operating Expenses (130.2) (137.6) 6% the
Slide 8: Group Cash + Marketable Securities Balance
Group Cash + Marketable Securities balance ($m) 13.2 45.4 -19.8 -20.0 -33.2 -7.9 -16.5 1.0 -11.1 149.3 134.9 127.0 100.4 30 Jun 2024 30 Jun 2025 Cash balance Cash balance Continuing operations1 Discontinued operations Investing & Financing (29% net cash operations Continuing used) 1 (16% net cash us
Slide 9: Segment Performance
S pharma Segment Performance
Slide 10: Continued Improvement with Growth in FY25 Direct Contribution
Continued Improvement with Growth in FY25 Direct Contribution1 $21.2m increase in direct contribution driven by 76% increase in Women’s Health FY25 Total Direct Contribution $109.7m FY24 Total Direct Contribution Dermatology $44.3m $7.4m Women’s Health $35.2m $88.5m +$21.2m $40.2m International $9.0
Slide 11: Segment Performance
Segment Performance 24% overall increase in direct contribution Reported results Change Change vs (A$million) 1HFY24 2HFY24 1HFY25 2HFY25 FY24 FY25 vs FY24 1HFY24 2HFY24 1HFY25 2HFY25 FY24 FY25 FY24 1 Revenue Gross profit Dermatology 80.9 93.9 81.4 72.7 174.9 154.1 -12% Dermatology 36.6 47.3 43.4 39
Slide 12: Women's Health
S pharma © Women’s Health
Slide 13: Women's Health: Continued Strong Growth
Women’s Health: continued strong growth FY25 Highlights Future growth drivers for Women’s Health • Continued focus on sales execution, targeted marketing and channel • Continue to invest into product awareness via Medical Science Liaisons management has delivered improved sales, higher margins and d
Slide 14: NEXTSTELLIS FY25 Demand Cycles Up 30%
NEXTSTELLIS® FY25 demand cycles1 up 30%, Net Sales up 41% to US$42.5 million NEXTSTELLIS® Quarterly US Demand Cycles (thousands) NEXTSTELLIS ® US Net Sales (US$m) and growth 8.4% 41% 2.0% 168 5.8% 4.1% 100.0% 45.0 42.5 160.0 10.4% 152 155 146 90.0% 40.0 5.9% 138 140.0 11.3% 80.0% 113% 19.1% 118 125
Slide 15: Driving Demand with IMVEXXY and BIJUVA for Menopausal Patients
Driving demand with IMVEXXY® and BIJUVA® for menopausal patients Licensed Portfolio Demand TRx (thousands)1 Production issue caused temporary ANNOVERA® Demand softness: sales force IMVEXXY® sample supply constraints/demand BIJUVA® upgrade expected to benefit softness; issue resolved in Q4FY25 Awaren
Slide 16: Dermatology
Dermatology
Slide 17: Dermatology: Improved Product Mix and Channel Growth
Dermatology: Improved product mix, solid channel growth from disintermediation strategy FY25 Highlights Channel Strategy Update • Continued improvement in product mix for Dermatology leading to • Continued deployment of disintermediation strategy across both higher gross margins despite lower revenu
Slide 18: TWYNEO and EPSOLAY - New Dermatology Products acquired from Sol-Gel
TWYNEO® and EPSOLAY® - New Dermatology Products acquired from Sol-Gel Technologies Limited (NASDAQ:SLGL) • Acquired two approved branded products TWYNEO® (acne) and EPSOLAY® (rosacea) from Sol-Gel for sale and distribution in the US • US$10m upfront and US$6m 6 months later • Combined sales of US$40
Slide 19: Dermatology Margins and Direct Contribution Growth
Dermatology margins and direct contribution growth Dermatology Revenue and Gross Margin (US$m/%) Commentary $140 • Year-on-year revenue decline due to competitive launches against $120 AG ORACEA®, loss of some insurance coverage on RHOFADE®, and continued declines in the branded oral antibiotic mark
Slide 20: International
International
Slide 21: International: Investing to Create New Opportunities
International: investing to create new opportunities FY25 Highlights • International revenue increased 7% to $75.6m (versus $70.7m pcp), gross profit increased by 1% to $21.5m • Expanded exclusive distribution agreement with a key partner for the exclusive distribution of 200mg KADIAN® in Canada • i
Slide 22: Scheme of Arrangement with Cosette Pharmaceuticals
Scheme of Arrangement (Scheme) with Cosette Pharmaceuticals, Inc (Cosette) • The Scheme with Cosette remains ongoing with court hearing to commence 22 September and expected to run for a matter of weeks • Second court date to approve the Scheme not yet scheduled – anticipate this to be mid to late O
Slide 23: FY26 Focus and Outlook
FY26 focus and outlook Women’s Health Dermatology International Continue to optimise profit potential of Differentiate channel solution to enable Drive International profit via new current Women’s Health asset portfolio preferred solution for patients, revenue streams and continuation of prescribers
Slide 24: Contacts
Contacts For further information contact: Dr Tom Duthy Investor Relations +61 402 493 727 ir@maynepharma.com You deserve tomorrow. 24